Skip to main content

Table 1 Prevalence of antibodies to HERV-K10 Gag and Pol peptides in different populations

From: Increased seroreactivity to HERV-K10 peptides in patients with HTLV myelopathy

 

VBD

LGLL

HTLVt

HTLVm

HTLVn

MS

Peptides

#tested

#pos (%)

#tested

#pos (%)

#tested

#pos (%)

#tested

#pos (%)

#tested

#pos (%)

#tested

#pos (%)

HERV-K10 Gag*

100

7(7)

53

0(0)

74

18(24)

16

14(88)

58

4(7)

83

9(11)

HERV-K10 Pol+

100

0(0)

53

3(6)

74

21(28)

16

15(94)

58

6(10)

83

13(16)

  1. *HERV-K10 Gag VBD vs. LGLL, p = 0.047; VBD vs. all HTLV+, p = 0.001; VBD vs. HTLV + myelopathy, p = < 0.001: VBD vs. HTLV + non-myelopathy, p = 0.626; VBD vs. multiple sclerosis, p = 0.256; HTLV + myelopathy vs. HTLV + non-myelopathy, p = <0.001; HTLV + myelopathy vs. MS p = < 0.001.
  2. +HERV-K10 Pol VBD vs. LGLL, p = 0.040; VBD vs. all HTLV+, p = 0.001; VBD vs. HTLV + myelopathy, p = < 0.001: VBD vs. HTLV + non-myelopathy, p = 0.002; VBD vs. multiple sclerosis, p = < 0.001; HTLV + myelopathy vs. HTLV + non-myelopathy, p = <0.001; HTLV + myelopathy vs. MS, p = < 0.001.
Back to article page

Virology Journal

ISSN: 1743-422X